GENENTECH, INC for GENENTECH INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
trade Promotion Authority; Issues relating to U.S. trade policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE RAAB | Director |
Taxation/Internal Revenue Code TAX
Issues related to tax reform and tax extenders; Issues relating to corporate tax reform including the R&D tax credit and taxation of foreign-owned corporations;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
Copyright/Patent/Trademark CPT
Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; general IP issues, transpacific partnership agreement;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| KATHERINE RAAB | Director |
Health Issues HCR
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program; Reform of 340B program. Advocacy and education regarding HR 6 - 21st Century Cures Act; Implementation issues related to the Pharmaceutical Quality, Security and Accountibilty Act (P.L. 113-54) S. 2007, Preventing Regulatory Overreach to Enhance Care Technology Act of 2014, Cancer Patient Protection; Ongoing issues related to the implementation of the Affordable Care Act - 21st H.R. 6- 21st Century Cures Act; Advocacy on issues related to the Pan-American Health Organization, the 340B during pricing program and Medicare Part B and pandemic planning. Drug pricing under 340B program; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectivness research, and FDA approval of follow-on biologics; Publaw 111-152, the Health Care and Education Reconcilation Act of 2010 - Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Meetings with Administration and congressional staff on coverage/payment issues related to cancer biotherapeutics, 340B program; Meetings with Administration staff concerning the President's precision medicine initiative
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| ANNA GRIFFIN | Sr. Director |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
issues related to H.R. 6, the 21st Century CURES Act; Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual eligible demonstrations and Medicare Part B reimbursement for physicians and related provisions of The Affordable Care Act; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Public Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
Issues related to FDA & HHS program funding, FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills.; Issues to theFY 2016 Department of Labor, Health and Human Services and Education , and Related Agencies Appropriations and issue related to S. Con. Res. 11 and H. Con Res
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNA GRIFFIN | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.